ES2157307T3 - Composicion topica que contiene un antagonista de sustancia p. - Google Patents

Composicion topica que contiene un antagonista de sustancia p.

Info

Publication number
ES2157307T3
ES2157307T3 ES95402502T ES95402502T ES2157307T3 ES 2157307 T3 ES2157307 T3 ES 2157307T3 ES 95402502 T ES95402502 T ES 95402502T ES 95402502 T ES95402502 T ES 95402502T ES 2157307 T3 ES2157307 T3 ES 2157307T3
Authority
ES
Spain
Prior art keywords
irritant
product
composition containing
antagonist
substance antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95402502T
Other languages
English (en)
Inventor
Lacharriere Olivier De
Lionel Breton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LOreal SA
Original Assignee
LOreal SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9469931&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2157307(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by LOreal SA filed Critical LOreal SA
Application granted granted Critical
Publication of ES2157307T3 publication Critical patent/ES2157307T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/046—Tachykinins, e.g. eledoisins, substance P; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)

Abstract

LA INVENCION SE REFIERE A UNA COMPOSICION TERAPEUTICA DE APLICACION TOPICA QUE CONTIENE AL MENOS UN PRODUCTO DE EFECTO SECUNDARIO IRRITANTE Y UN ANTAGONISTA DE SUSTANCIA P PARA REDUCIR INCLUSO ELIMINAR EL EFECTO IRRITANTE DE ESTE PRODUCTO. SE REFIERE TAMBIEN A LA UTILIZACION DE UN ANTAGONISTA DE SUSTANCIA P PARA LA PREPARACION DE UNA COMPOSICION FARMACEUTICA EN LA APLICACION TOPICA QUE CONTIENE AL MENOS UN PRODUCTO DE EFECTO SECUNDARIO IRRITANTE PARA REDUCIR INCLUSO ELIMINAR EL EFECTO IRRITANTE DE ESTE PRODUCTO. EL ANTAGONISTA DE SUSTANCIA P PUEDE SER UN COMPUESTO PEPTIDICO O UN COMPUESTO NITROGENADO O UN COMPUESTO HETEROCICLICO NITROGENADO, AZUFRADO U OXIGENADO.
ES95402502T 1994-12-19 1995-11-09 Composicion topica que contiene un antagonista de sustancia p. Expired - Lifetime ES2157307T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9415253A FR2728166A1 (fr) 1994-12-19 1994-12-19 Composition topique contenant un antagoniste de substance p

Publications (1)

Publication Number Publication Date
ES2157307T3 true ES2157307T3 (es) 2001-08-16

Family

ID=9469931

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95402502T Expired - Lifetime ES2157307T3 (es) 1994-12-19 1995-11-09 Composicion topica que contiene un antagonista de sustancia p.

Country Status (17)

Country Link
US (2) US5824650A (es)
EP (1) EP0722736B1 (es)
JP (1) JPH08208505A (es)
AR (1) AR002007A1 (es)
AT (1) ATE198986T1 (es)
BR (1) BR9505408A (es)
CA (1) CA2165521C (es)
DE (1) DE69520032T2 (es)
DK (1) DK0722736T3 (es)
ES (1) ES2157307T3 (es)
FR (1) FR2728166A1 (es)
GR (1) GR3035652T3 (es)
HU (1) HU218936B (es)
MX (1) MX9505182A (es)
PL (1) PL311918A1 (es)
PT (1) PT722736E (es)
RU (1) RU2124353C1 (es)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6203803B1 (en) 1994-12-14 2001-03-20 Societe L'oreal S.A. Use of a substance P antagonist in a cosmetic composition, and the composition thus obtained
US6139850A (en) * 1994-12-21 2000-10-31 Cosmederm Technologies Formulations and methods for reducing skin irritation
US7404967B2 (en) * 1994-12-21 2008-07-29 Cosmederm, Inc. Topical product formulations containing strontium for reducing skin irritation
FR2732221B1 (fr) * 1995-03-28 1997-04-25 Oreal Utilisation d'un antagoniste de cgrp pour traiter les rougeurs cutanees d'origine neurogene et composition obtenue
US20040071762A1 (en) * 1996-05-29 2004-04-15 Scotia Holdings Plc Diagnostic test for schizophrenia, using niacin
US7217714B1 (en) 1998-12-23 2007-05-15 Agouron Pharmaceuticals, Inc. CCR5 modulators
PE20001420A1 (es) 1998-12-23 2000-12-18 Pfizer Moduladores de ccr5
DE19924277A1 (de) * 1999-05-27 2000-11-30 Beiersdorf Ag Zubereitungen von Emulsionstyp W/O mit erhöhtem Wassergehalt mit einem Gehalt an mittelpolaren Lipiden und Siliconemulgatoren und gegebenenfalls kationischen Polymeren
US6861397B2 (en) * 1999-06-23 2005-03-01 The Dial Corporation Compositions having enhanced deposition of a topically active compound on a surface
US6107261A (en) 1999-06-23 2000-08-22 The Dial Corporation Compositions containing a high percent saturation concentration of antibacterial agent
RU2161974C1 (ru) * 2000-01-20 2001-01-20 Общество с ограниченной ответственностью "Клиника Института биорегуляции и геронтологии" Лечебно-профилактическое средство для ухода за кожей (варианты)
KR100366439B1 (ko) * 2000-02-21 2003-01-09 주식회사 대웅 상피세포 성장인자를 유효성분으로 하는 안정한 약제학적조성물
US6689399B1 (en) 2000-03-16 2004-02-10 James R. Dickson Transdermal delivery of an anti-inflammatory composition
US8512718B2 (en) 2000-07-03 2013-08-20 Foamix Ltd. Pharmaceutical composition for topical application
GB0029018D0 (en) * 2000-11-28 2001-01-10 Strakan Group Plc Dermatological formulations
ITPD20010187A1 (it) * 2001-07-23 2003-01-23 Cutech Srl Trattamento del follicolo polifero, in particolare contro la caduta dei capelli
RU2190394C1 (ru) * 2001-11-08 2002-10-10 ОАО Нижегородский химико-фармацевтический завод Фармацевтический состав, обладающий противогрибковой активностью, и способ его получения
US7820186B2 (en) 2001-12-21 2010-10-26 Galderma Research & Development Gel composition for once-daily treatment of common acne comprising a combination of benzoyl peroxide and adapalene and/or adapalene salt
EP1380639B1 (en) * 2002-01-15 2009-09-09 OOO "Nauchno-Proizvodstvennoe Obiedinenie "Opytnaya Vodno-Analiticheskaya Laboratoria" Method for producing a water-alcohol solution
RU2216582C2 (ru) * 2002-01-15 2003-11-20 Сорокин Валерий Николаевич Способ получения водно-спиртового раствора и алкогольный, фармацевтический и косметический продукты, изготовленные с его использованием
RU2243992C2 (ru) * 2002-03-28 2005-01-10 Сорокин Валерий Николаевич Способ получения водно-спиртового раствора и алкогольный, фармацевтический и косметический продукты, изготовленные с его использованием
JP4473491B2 (ja) * 2002-05-28 2010-06-02 株式会社資生堂 毛穴縮小剤
US6723755B2 (en) 2002-06-12 2004-04-20 Piotr Chomczynski Method of treating rosacea
IL152486A0 (en) 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
US8486376B2 (en) 2002-10-25 2013-07-16 Foamix Ltd. Moisturizing foam containing lanolin
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
US20080138296A1 (en) 2002-10-25 2008-06-12 Foamix Ltd. Foam prepared from nanoemulsions and uses
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US7700076B2 (en) 2002-10-25 2010-04-20 Foamix, Ltd. Penetrating pharmaceutical foam
AU2003279493B2 (en) 2002-10-25 2009-08-20 Foamix Pharmaceuticals Ltd. Cosmetic and pharmaceutical foam
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US8119109B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Foamable compositions, kits and methods for hyperhidrosis
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US8119150B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Non-flammable insecticide composition and uses thereof
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
US7575739B2 (en) 2003-04-28 2009-08-18 Foamix Ltd. Foamable iodine composition
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
US8486374B2 (en) 2003-08-04 2013-07-16 Foamix Ltd. Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
RU2257204C2 (ru) * 2003-08-12 2005-07-27 Открытое Акционерное Общество "Фармакон" (ОАО "Фармакон") Противогрибковая гелевая фармацевтическая композиция и способ ее получения
US6902723B2 (en) * 2003-08-14 2005-06-07 The Gillette Company Enhanced efficacy antiperspirant compositions containing strontium
US6923952B2 (en) * 2003-08-14 2005-08-02 The Gillette Company Enhanced efficacy antiperspirant compositions containing strontium or calcium
US7812057B2 (en) * 2004-08-25 2010-10-12 Molecular Research Center, Inc. Cosmetic compositions
US7872050B2 (en) * 2005-03-14 2011-01-18 Yaupon Therapeutics Inc. Stabilized compositions of volatile alkylating agents and methods of using thereof
US8501818B2 (en) * 2005-03-14 2013-08-06 Ceptaris Therapeutics, Inc. Stabilized compositions of alkylating agents and methods of using same
US20110039943A1 (en) * 2005-03-14 2011-02-17 Robert Alonso Methods for treating skin disorders with topical nitrogen mustard compositions
MX2007014101A (es) 2005-05-09 2009-02-13 Foamix Ltd Vehiculo espumable y composiciones farmaceuticas del mismo.
EP1888033B1 (en) * 2005-06-09 2014-02-19 Meda AB Method and composition for treating inflammatory disorders
US20070154448A1 (en) * 2005-11-22 2007-07-05 Ted Reid Methods and compositions using Substance P to promote wound healing
MY177591A (en) 2006-10-16 2020-09-22 Lion Corp Nk1 receptor antagonist composition
US20080260655A1 (en) 2006-11-14 2008-10-23 Dov Tamarkin Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
FR2910321B1 (fr) 2006-12-21 2009-07-10 Galderma Res & Dev S N C Snc Gel creme comprenant au moins un retinoide et du peroxyde de benzole
CN101720226B (zh) * 2007-05-11 2013-01-30 芦荟研究实验室公司 用于皮肤增强的芦荟制剂
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US9439857B2 (en) 2007-11-30 2016-09-13 Foamix Pharmaceuticals Ltd. Foam containing benzoyl peroxide
US8518376B2 (en) 2007-12-07 2013-08-27 Foamix Ltd. Oil-based foamable carriers and formulations
WO2009090495A2 (en) 2007-12-07 2009-07-23 Foamix Ltd. Oil and liquid silicone foamable carriers and formulations
EP2242476A2 (en) 2008-01-14 2010-10-27 Foamix Ltd. Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
SI2273876T1 (sl) * 2008-03-27 2019-09-30 Helsinn Healthcare Sa Stabilizirani sestavki alkilirajočih sredstev in metod za uporabo le-teh
EP2177208A1 (en) * 2008-10-17 2010-04-21 Ferrer Internacional, S.A. Pharmaceutical topical compositions
US7833829B2 (en) * 2008-10-28 2010-11-16 Honeywell International Inc. MEMS devices and methods of assembling micro electromechanical systems (MEMS)
JP5425229B2 (ja) * 2009-02-24 2014-02-26 ノバルティス アーゲー Ｎｋ受容体アンタゴニストの使用
WO2010125470A2 (en) 2009-04-28 2010-11-04 Foamix Ltd. Foamable vehicle and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
WO2011013009A2 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
CA2769677A1 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
MX359879B (es) 2009-10-02 2018-10-12 Foamix Pharmaceuticals Ltd Composiciones tópicas de tetraciclina.
RU2485955C2 (ru) * 2010-11-17 2013-06-27 Леонид Леонидович Клопотенко Фармацевтическая композиция, содержащая флуконазол, и/или кетоконазол, и/или тербинафин и липосомы для местного применения
KR101729096B1 (ko) 2012-03-21 2017-04-21 코스메덤 바이오사이언스, 인코퍼레이티드 통증, 가려움증 및 염증을 치료하기 위한 국소 투여된 스트론튬-함유 복합체
US11235002B2 (en) 2015-08-21 2022-02-01 Galleon Labs Llc Strontium based compositions and formulations for pain, pruritus, and inflammation
CA2978573A1 (en) 2016-09-08 2018-03-08 Foamix Pharmaceuticals Ltd. Compositions and methods for treating rosacea and acne
US11708135B2 (en) 2018-05-30 2023-07-25 Philip John Milanovich Waste management system

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE297062C (es) *
LU65373A1 (es) * 1972-05-17 1973-11-23
US3772431A (en) * 1972-09-21 1973-11-13 W Mlkvy Effervescent mouthwash tablet
US3888976A (en) * 1972-09-21 1975-06-10 William P Mlkvy Zinc and strontium ion containing effervescent mouthwash tablet
US4477439A (en) * 1981-04-13 1984-10-16 Walter J. Monacelli Treatment of irritated and excoriated areas around the stoma of ostomy patients
JPS5921656A (ja) 1982-07-28 1984-02-03 Takeda Chem Ind Ltd ポリペプチド誘導体
US4472305A (en) 1983-05-17 1984-09-18 Sterling Drug Inc. Hexapeptide amides
DE3338957A1 (de) * 1983-10-27 1985-05-15 Keyhan Dipl.-Ing. 6908 Wiesloch Ghawami Enthaarungsmittel
LU85544A1 (fr) 1984-09-19 1986-04-03 Cird Derives heterocycliques aromatiques,leur procede de preparation et leur application dans les domaines therapeutique et cosmetique
LU85849A1 (fr) 1985-04-11 1986-11-05 Cird Derives benzonaphtaleniques,leur procede de preparation et leur application dans les domaines pharmaceutiques et cosmetiques
IT1214611B (it) * 1985-05-22 1990-01-18 Schiena Ricerche Composti per uso cosmetico dermatologico e relative composizioni.
EP0217975B1 (de) * 1985-10-08 1991-12-04 Psori-Med Ag Salzmischung zur Behandlung der Schuppenflechte (Psoriasis) und anderer Hautkrankheiten
US4986981A (en) * 1986-07-07 1991-01-22 Den Mat Corporation Toothpaste having low abrasion
US5091171B2 (en) * 1986-12-23 1997-07-15 Tristrata Inc Amphoteric compositions and polymeric forms of alpha hydroxyacids and their therapeutic use
US4839465A (en) 1987-01-20 1989-06-13 Sterling Drug Inc. Di-(D-tryptophyl and/or tetrahydropyridoindolylcarbonyl)-containing peptide amides and process for preparation thereof
SE8701372L (sv) * 1987-04-02 1988-10-03 Boliden Ab Foerfarande och medel foer konservering av hoe
US4910317A (en) 1987-07-14 1990-03-20 Warner-Lambert Company Benzofurans and benzothiophenes having antiallergic activity and method of use thereof
IE64995B1 (en) 1987-07-14 1995-09-20 Warner Lambert Co Novel benzothiophenes having antiallergic activity and both novel and other selected benzothiophenes having activity for treating acute respiratory distress syndrome
US4931459A (en) 1987-07-14 1990-06-05 Warner-Lambert Company Method for treating acute respirator distress syndrome
LU87109A1 (fr) 1988-01-20 1989-08-30 Cird Esters et thioesters aromatiques,leur procede de preparation et leur utilisation en medecine humaine ou veterinaire et en cosmetique
GB8807921D0 (en) 1988-04-05 1988-05-05 Fujisawa Pharmaceutical Co Ws-9326 & its derivatives
US5187156A (en) 1988-03-16 1993-02-16 Fujisawa Pharmaceutical Co., Ltd. Peptide compounds, processes for preparation thereof and pharmaceutical composition comprising the same
GB8807246D0 (en) 1988-03-25 1988-04-27 Merck Sharp & Dohme Therapeutic agents
EP0360390A1 (en) 1988-07-25 1990-03-28 Glaxo Group Limited Spirolactam derivatives
DE3929411A1 (de) * 1988-09-22 1990-03-29 Siegfried Natterer Pharmazeutische zubereitung sowie verfahren zu ihrer herstellung
WO1990005525A1 (en) 1988-11-23 1990-05-31 Pfizer Inc. Quinuclidine derivatives as substance p antagonists
DE3903993A1 (de) * 1989-02-10 1990-08-16 Basf Ag Diarylsubstituierte heterocyclische verbindungen, ihre herstellung und arzneimittel daraus
US5164372A (en) 1989-04-28 1992-11-17 Fujisawa Pharmaceutical Company, Ltd. Peptide compounds having substance p antagonism, processes for preparation thereof and pharmaceutical composition comprising the same
JPH03119163A (ja) 1989-06-05 1991-05-21 Sequa Chemicals Inc 不織繊維用バインダー
US5202130A (en) * 1989-08-31 1993-04-13 The Johns Hopkins University Suppression of eczematous dermatitis by calcium transport inhibition
FR2654725B1 (fr) 1989-11-23 1992-02-14 Rhone Poulenc Sante Nouveaux derives de l'isoindolone, leur preparation et les compositions pharmaceutiques qui les contiennent.
FR2654726B1 (fr) 1989-11-23 1992-02-14 Rhone Poulenc Sante Nouveaux derives de l'isoindolone et leur preparation.
GB8929070D0 (en) 1989-12-22 1990-02-28 Fujisawa Pharmaceutical Co Peptide compounds,processes for preparation thereof and pharmaceutical composition comprising the same
UA41251C2 (uk) 1990-01-04 2001-09-17 Пфайзер, Інк. Гідровані азотвмісні гетероциклічні сполуки, похідні піперидину, фармацевтична композиція та спосіб пригнічення активності речовини р в організмі
US5232929A (en) 1990-11-28 1993-08-03 Pfizer Inc. 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use
ATE94399T1 (de) * 1990-01-29 1993-10-15 Wogepharm Gmbh Verfahren zur herstellung von mitteln zur therapie von hauterkrankungen.
WO1991012266A1 (fr) 1990-02-15 1991-08-22 Fujisawa Pharmaceutical Co., Ltd. Compose peptidique
US5344532A (en) 1990-03-09 1994-09-06 Joseph Adrian A Ultrasonic energy producing device
FR2662607B1 (fr) * 1990-05-30 1992-08-28 Oreal Composition destinee a etre utilisee pour freiner la chute des cheveux et pour induire et stimuler leur croissance, contenant des derives d'alkyl-2 amino-4 (ou dialkyl-2-4) pyrimidine oxyde-3 .
PL169187B1 (pl) 1990-05-31 1996-06-28 Pfizer Sposób wytwarzania podstawionych piperydyn PL PL PL
EP0532527B1 (en) 1990-06-01 1994-11-09 Pfizer Inc. 3-amino-2-aryl quinuclidines, process for their preparation and pharmaceutical compositions containing them
DE69114117T2 (de) 1990-12-21 1996-03-21 Fujisawa Pharmaceutical Co Neue Verwendung von Peptidderivat.
WO1992012151A1 (en) 1991-01-10 1992-07-23 Pfizer Inc. N-alkyl quinuclidinium salts as substance p antagonists
EP0499313B1 (en) 1991-02-11 1997-06-11 MERCK SHARP & DOHME LTD. Azabicyclic compounds, pharmaceutical compositions containing them and their use in therapy
EP0573522B1 (en) 1991-03-01 1994-12-14 Pfizer Inc. 1-azabicyclo[3.2.2]nonan-3-amine derivatives
BR9205807A (pt) 1991-03-26 1994-06-28 Pfizer Preparação estéreo-seletiva de piperidinas substituidas
FR2677361A1 (fr) 1991-06-04 1992-12-11 Adir Nouveaux peptides et pseudopeptides, derives de tachykinines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2676446B1 (fr) 1991-05-17 1993-08-06 Rhone Poulenc Rorer Sa Nouveaux derives du thiopyranopyrrole, leur preparation et les compositions pharmaceutiques qui les contiennent.
FR2676447B1 (fr) 1991-05-17 1993-08-06 Rhone Poulenc Rorer Sa Nouveaux derives du thiopyranopyrrole et leur preparation.
FR2676442B1 (fr) 1991-05-17 1993-08-06 Rhone Poulenc Rorer Sa Nouveau derives de perhydroisoindole, leur preparation et les compositions pharmaceutiques qui les contiennent.
FR2676443B1 (fr) 1991-05-17 1993-08-06 Rhone Poulenc Rorer Sa Nouveaux derives de perhydroisoindole et leur preparation.
FI935134A7 (fi) 1991-05-22 1993-11-19 Pfizer Substituoidut 3-aminokinuklidiinit
GB9113219D0 (en) 1991-06-19 1991-08-07 Fujisawa Pharmaceutical Co Peptide compound,processes for preparation thereof and pharmaceutical composition comprising the same
BR9206161A (pt) 1991-06-20 1995-10-31 Pfizer Derivados fluoroalcoxibenzilamino de heterociclos contendo nitrogénio
TW202432B (es) 1991-06-21 1993-03-21 Pfizer
US5288730A (en) 1991-06-24 1994-02-22 Merck Sharp & Dohme Limited Azabicyclic compounds, pharmaceutical compositions containing them and their use in therapy
WO1993001169A2 (en) 1991-07-05 1993-01-21 Merck Sharp & Dohme Limited Aromatic compounds, pharmaceutical compositions containing them and their use in therapy
ATE133657T1 (de) 1991-07-05 1996-02-15 Merck Sharp & Dohme Aromatische verbindungen, diese enthaltende pharmazeutische zusammensetzungen und ihre therapeutische anwendung
WO1993001159A1 (en) 1991-07-10 1993-01-21 Merck Sharp & Dohme Limited Fused tricyclic compounds, pharmaceutical compositions containing them and their use in therapy
DE69208089T2 (de) 1991-07-10 1996-08-22 Merck Sharp & Dohme Aromatische verbindungen diese enthaltende pharmazeutische zusammensetzungen und ihre therapeutische verwendung
MY110227A (en) 1991-08-12 1998-03-31 Ciba Geigy Ag 1-acylpiperindine compounds.
CA2112397A1 (en) 1991-08-20 1993-03-04 Raymond Baker Azacyclic compounds, processes for their preparation and pharmaceutical compositions containing them
FI941212L (fi) 1991-09-26 1994-03-15 Pfizer Fuusioituneet trisykliset, typpeä sisältävät heterosykliset yhdisteet
JP2553020B2 (ja) 1991-11-07 1996-11-13 吉富製薬株式会社 キヌクリジン化合物およびその医薬用途
FI942187L (fi) 1991-11-12 1994-05-11 Pfizer Asyklisiä etyleenidiamiinijohdannaisia aine P-reseptoriantagonisteina
CA2083891A1 (en) 1991-12-03 1993-06-04 Angus Murray Macleod Heterocyclic compounds, compositions containing them and their use in therapy
US5569662A (en) * 1992-03-23 1996-10-29 Pfizer Inc. Quinuclidine derivatives as substance P antagonists
DE4227203C2 (de) * 1992-08-17 1994-03-24 Kao Corp Gmbh Mittel und Verfahren zur Haarbehandlung
JP2656699B2 (ja) 1992-10-21 1997-09-24 ファイザー製薬株式会社 置換ベンジルアミノキヌクリジン
US5716625A (en) * 1994-12-21 1998-02-10 Cosmederm Technologies Formulations and methods for reducing skin irritation

Also Published As

Publication number Publication date
RU2124353C1 (ru) 1999-01-10
HU9503623D0 (en) 1996-02-28
PT722736E (pt) 2001-05-31
DE69520032T2 (de) 2001-05-23
JPH08208505A (ja) 1996-08-13
CA2165521A1 (fr) 1996-06-20
AR002007A1 (es) 1998-01-07
US5972892A (en) 1999-10-26
HU218936B (hu) 2001-01-29
FR2728166A1 (fr) 1996-06-21
ATE198986T1 (de) 2001-02-15
HUT74830A (en) 1997-02-28
PL311918A1 (en) 1996-06-24
GR3035652T3 (en) 2001-06-29
FR2728166B1 (es) 1997-02-07
CA2165521C (fr) 2002-07-16
BR9505408A (pt) 1997-10-28
EP0722736A1 (fr) 1996-07-24
US5824650A (en) 1998-10-20
DK0722736T3 (da) 2001-04-02
EP0722736B1 (fr) 2001-01-31
MX9505182A (es) 1997-02-28
DE69520032D1 (de) 2001-03-08

Similar Documents

Publication Publication Date Title
ES2157307T3 (es) Composicion topica que contiene un antagonista de sustancia p.
ES2147538A1 (es) Una locion capilar con propiedades mejoradas en su accion protectora del cabello y preventiva de su caida, y de reduccion de los efectos externos de la alopecia androgenetica y con ello de la caida del cabello.
AR022008A1 (es) Una composicion de liberacion controlada de galantamina, un proceso para la preparacion de la misma, y el uso de dicha composicion para la preparacion de un medicamento
PT100963A (pt) Composicoes farmaceuticas para aplicacao topica de elevada penetracao atraves da pele que compreendem certos polimeros nao-ionicos especificos
EE04965B1 (et) Imidasoimidasoolid ja triasoolid kui p?letikuvastased hendid, nende kasutamine ravimite valmistamiseks ning farmatseutiline kompositsioon
ATE324907T1 (de) Verbindung und arzneizusammensetzung zur verabreichung von wirkstoffen
AU6408298A (en) Essential oil composition
MY119403A (en) Novel compounds with analgesic effect.
ES2133426T3 (es) Combinaciones de productos activos fungicidas.
AR004700A1 (es) 1alfa, 26 dihidroxi-d-homo-vitamina d3, una composicion farmaceutica que la comprende, un procedimiento para su preparacion y el uso de los mismos en laelaboracion de un medicamento
AU2740797A (en) Androstene derivatives
AR021370A1 (es) Composiciones farmaceuticas inyectables estabilizadas que contienen agentes anti-neoplasicos taxoides
HUP9602498A2 (hu) Antimikrobiális hatású gyógyászati készítmények
UA35611C2 (uk) Композиція місцевого застосування для інгібування росту волос у ссавців, спосіб із її використанням та композиція місцевого застосування для доставки водорозчинного фармакологічного засобу до шкіри
DE69923336D1 (de) Oral anzuwendende buprenorphinhaltige arzneimittel
AR003176A1 (es) Una composicion farmaceutica para inhibir el crecimiento de cancer
IT1263840B (it) Formulazioni orali di ubidecarenone in forma di capsule
ES2124983T5 (es) Utilizacion de un antagonista de substancia p para el tratamiento de las manchas rojas cutaneas de origen neurogeno.
ES2174054T3 (es) Composiciones farmaceuticas acuosas liquidas que comprenden alginato sodico y bicarbonato potasico.
ES2132556T3 (es) Nuevo derivado de benzo-tiadiazina, su procedimiento de preparacion y las composiciones farmaceuticas que lo contienen.
AR011437A1 (es) Composicion farmaceutica para el tratamiento de la migrana y el uso de la misma en la preparacion de un medicamento.
ES2105605T3 (es) Antagonistas de taquiquinina, su preparacion y utilizacion en formulaciones farmaceuticas.
ES2123821T3 (es) Formulacion de pulverizacion que tiene un efecto refrescante.
ES2102273T3 (es) Utilizacion de un compuesto vegetal para la fijacion de un perfume en una composicion cosmetica y/o dermatologica.
AU7941294A (en) Composition for the treatment or prevention of herpes

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 722736

Country of ref document: ES